



HHS Public Access

Author manuscript

Am J Ophthalmol. Author manuscript; available in PMC 2022 October 01.

Published in final edited form as:

Am J Ophthalmol. 2022 October ; 242: 254. doi:10.1016/j.ajo.2022.07.018.

CORRIGENDUM TO PHASE 1B RANDOMIZED CONTROLLED STUDY OF SHORT COURSE TOPICAL RECOMBINANT HUMAN NERVE GROWTH FACTOR (RHNGF) FOR NEUROENHANCEMENT IN GLAUCOMA: SAFETY, TOLERABILITY, AND EFFICACY MEASURE OUTCOMES. AM J OPHTHALMOL 2022;234:223–234

**GALA BEYKIN,
LAUREL STELL,
MUHAMMAD SOHAIL HALIM,
MARIANA NUÑEZ,
LILIA POPOVA,
BAC T. NGUYEN,
SYLVIA L. GROTH,
AMY DENNIS,
ZHONGQIU LI,
MELISSA ATKINS,
TOM KHAVARI,
SOPHIA Y. WANG,
ROBERT CHANG,
ANN C. FISHER,
YASIR J. SEPAH,
JEFFREY L. GOLDBERG**

The Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, United States

The author regrets that in the February 2022 issue, Jeffrey L. Goldberg should have been listed as first author of the above Thesis according to American Ophthalmological Society policy. The corrected author list should read as follows:

Jeffrey L. Goldberg, Gala Beykin, Laurel Stell, Muhammad Sohail Halim, Mariana Nuñez, Lilia Popova, Bac T. Nguyen, Sylvia L. Groth, Amy Dennis, Zhongqiu Li, Melissa Atkins, Tom Khavari, Sophia Y. Wang, Robert Chang, Ann C. Fisher, Yasir J. Sepah.